South Korean medical aesthetics device maker Classys presented its global expansion strategy at the Jefferies Healthcare Conference in the US, targeting 15% of total revenue from North America by 2030. The company highlighted its installed base of 45,000 devices across 80 countries and a next-generation energy-based device (EBD) platform, drawing strong interest from international investors. For overseas buyers and distributors, Classys’ growing North American footprint and consumables-driven business model signal new partnership opportunities in the aesthetic device supply chain.
Conference presence and market signal
Classys, led by CEO Choi Yun-seok, participated in the Jefferies Healthcare Conference—Europe’s largest healthcare investment event with over 500 companies and 3,000 investors—marking its debut as a leading Korean aesthetic device firm. Kim Rae-hee, Executive Vice President and Head of Marketing, presented the company’s differentiated competitiveness and global expansion plans, reinforcing Classys’ position in the global medical aesthetics market.
North America performance and device sales
Classys reported that its cumulative installed base of monopolar radiofrequency (MRF) devices in North America surpassed 300 units last year. Following the launch of its microneedle radiofrequency (MNRF) device this year, combined sales of MRF and MNRF devices exceeded 100 units in Q1 alone. The company also anticipates regulatory approval for a high-intensity focused ultrasound (HIFU) device next year, supporting its 2030 North America revenue target.
Consumables model and brand recognition
Investors responded positively to Classys’ business model, which generates recurring consumables revenue after device sales, along with its country-specific product portfolio strategy. The company’s combination treatment protocols have gained traction among local clinicians and consumers, with Forbes citing the procedure as one of the most popular aesthetic treatments. Brand awareness is further boosted by advertising in New York’s Times Square and Hollywood.
Global sales momentum and regulatory progress
Classys aims to sell 1,000 units of its Quadcay device globally this year, with sales ramping up in the US and Thailand. Ultraformer and Volumer are seeing rapid revenue growth in key European markets. In Japan, the company is preparing to secure orders from large clinic chains, while Volumer’s regulatory approval in China is expected within the year. Combined annual global sales of these two products are projected to exceed 5,000 units, supporting the company’s 2026 revenue guidance of KRW 490 billion.
What buyers should watch
For overseas importers and distributors, Classys’ expanding North American presence and consumables-driven revenue model present potential partnership opportunities. The company’s multi-device platform strategy—spanning MRF, MNRF, and HIFU—offers a diversified product lineup for clinics. Buyers should monitor Classys’ regulatory progress in China and Japan, as well as its growing installed base in Europe and the US, which may signal increased demand for consumables and after-sales support.
Source: Read the original report | Published: June 05, 2026